knowledge -WSS

knowledge

author：leisure time 2025-09-06 04:14:00 - browse：5

The Food and Drug Administration is poised to tell drug and medical device makers how to better include people of color in the clinical trials that test whether products work and are safe, an agency official said Wednesday. Those guidelines are five months late.

To ensure that drugs work for everyone, they must be tested on a representative sample of people. But researchers have found that many clinical trials exclude the people of color who are often most affected by the diseases that drugs treat.

To help fix that problem, Congress passed a law requiring companies to give the FDA their plans for diversifying clinical trials. As part of that process, the agency was expected to issue guidance by the end of last year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： BioMarin wins approval for gene therapy to treat hemophilia A

WSS

Cassava reveals details — and problems — with Alzheimer's study

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Testing for cancer recurrence creates a new limbo for patients

Why Sanofi got shellacked over its spinoff

New air purifier tech could be key to improving indoor air quality

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

knowledge

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

knowledge

Duchenne breakthrough therapy leaves behind pioneering families

Hollywood unions extend contract negotiations for actors

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Why Sanofi got shellacked over its spinoff

Novavax promises a turnaround & Lilly roils the obesity market

Hollywood unions extend contract negotiations for actors

In Memoriam: Notable people who died in 2023

Jerome Adams on the need for new antivirals for Covid

Medicare proposal to cover medical devices draws a mixed reaction

FDA approval of Sarepta Duchenne genetic therapy gives me hope

focus

Telehealth options flood the market as retailers push virtual care

The pink breast cancer awareness ribbon needs a redesign

Meta's Zuckerberg and Chan on track to put $50 billion into science

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Eli Lilly to pay $200M for Beam’s stake in gene

WHO may add ‘noma' to its list of neglected tropical diseases

hotspot

hotspot

entertainment

leisure time